– USA, CA – DNAnexus, Inc., the leader in biomedical informatics and data management, today announced the appointment of Jeff Margolis to its Board of Directors, following a $200m financing round led by Blackstone.
“We’re thrilled to welcome Jeff to our Board of Directors. He is a passionate leader with a proven track record of commercializing innovative healthcare technologies that solve urgent and complex healthcare challenges. His advice and perspective will be invaluable as we look to drive the global adoption of our leading platform and position the company for long-term success,” said CEO, Richard Daly.
About
Mr. Margolis’ extensive industry experience includes 20 years as the CEO and/or chairman and another decade as CITO at publicly traded and private healthcare technology companies. He most recently served as the Chairman and CEO at Welltok, Inc., where he led the company from a pre-revenue startup to a leading enterprise consumer activation company. Before joining Welltok, Inc., Mr. Margolis founded and spent 14 years as CEO and Chairman of TriZetto Corporation, the first vertical SaaS enterprise software company.
Mr. Margolis currently serves as Chairman at NextGen Healthcare (NASDAQ: NXGN), Vice-Chairman at TriNetX, and as a board member at Alignment Healthcare (NASDAQ: ALHC), Hydrogen Health, and Grin. He serves as Chairman of the Hoag Clinic and the University of California at Irvine’s Center for Digital Transformation. Mr. Margolis is a leadership fellow with the National Association of Corporate Directors and a member of the American Institute of Certified Public Accountants with a Certified Global Management Accountant designation. He holds a bachelor of science degree with high honors in business administration–management information systems from the University of Illinois at Urbana-Champaign.
About DNAnexus
DNAnexus is a leading provider of secure, scalable, and intuitive biomedical data analysis software and bioinformatics applications for the life sciences and healthcare communities. The company actively manages and supports more than 65 petabytes of complex genomic, multi-omic, and clinical datasets on behalf of a growing network of collaborations with large-scale biobanks, as well as leading pharmaceutical, clinical diagnostic, academic research, and government organizations. Scientists across 48 countries are now using the highly collaborative, cloud-based, end-to-end platform to gain data-driven insights that can advance scientific discovery, accelerate precision medicine, and improve patient care.
For more information: https://www.dnanexus.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.